Thinly traded nano cap Parallax Health Sciences (OTCPK:PRLX +13%) is, yet another, would-be player in the mad dash for a rapid screening test for COVID-19.
Today, it announced that
subsidiary Parallax Diagnostics intends to in-license and develop
monoclonal and polyclonal antibodies for such a test based on its
VT-1000 immunoassay platform. Available resources appear to be an issue
since it is seeking partners to accelerate the development.
Test-related tickers: Aytu BioScience (AYTU -17.3%), Co-Diagnostics (CODX +63.6%), Thermo Fisher Scientific (TMO -4.7%), Abbott (ABT -3.8%), Roche (OTCQX:RHHBY N/A), Chembio Diagnostics (CEMI -1.3%), Becton, Dickinson (BDX -2.7%), Luminex (LMNX -2.9%)
https://seekingalpha.com/news/3550582-parallax-health-up-13-on-planned-coronavirus-test
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.